Welcome to HSC

Field	Query

	Field	Term

General Information:

Id:	2,140
Organism:	Mus musculus
Strain:	C57Bl/6 female mice, 6 week old
Reference:	Wilson A et al.(2008) Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135: 1118-1129 [PMID: 19062086]

Interaction Information:

Comment	Around 70% of the HSC (CD34negLSKCD150+48-) population are in G0, and less than 2% are actively cycling, thus making them the most rare and by far the most quiescent LSK cell type. In contrast, 7-fold more of the CD34+LSK CD150+48- cells (MPP1) are actively cycling, and only 39% are in G0. As expected, MPPs expressing CD48 and CD135 are highly proliferative. [Method: in vitro: cell cycle analysis using Ki67-FITC and DAPI.]
Formal Description Interaction-ID: 17705	immunophenotype HSC (CD34-CD135-CD150+CD48-KSL) increases_activity of process quiescence about 70% are in G0 phase in vitro

Comment	Around 70% of the HSC (CD34negLSKCD150+48-) population are in G0 and less than 2% are actively cycling, thus making them the most rare and by far the most quiescent LSK cell type. In contrast, 7-fold more of the CD34+LSK CD150+48- cells (MPP1) are actively cycling, and only 39% are in G0. As expected, MPPs expressing CD48 and CD135 are highly proliferative. [Method: in vitro: cell cycle analysis using Ki67-FITC and DAPI.]
Formal Description Interaction-ID: 17707	immunophenotype MPP (CD34+CD48-CD150+CD135-KSL) decreases_activity of process quiescence compared to the CD34- population; about 40% are in G0 phase in vitro

Comment	Around 70% of the HSC (CD34negLSKCD150+48-) population are in G0 and less than 2% are actively cycling, thus making them the most rare and by far the most quiescent LSK cell type. In contrast, 7-fold more of the CD34+LSK CD150+48- cells (MPP1) are actively cycling, and only 39% are in G0. As expected, MPPs expressing CD48 and CD135 are highly proliferative. [Method: in vitro: cell cycle analysis using Ki67-FITC and DAPI.]
Formal Description Interaction-ID: 17708	immunophenotype MPP (CD34+CD48+CD150-CD135+KSL) decreases_activity of process quiescence compared to the CD135- population; about 6% are in G0 phase in vitro

Comment	By modeling BrdU decay in LRC-HSCs, over time we can reveal the presence of a dormant population that comprises about one-seventh of the CD34negLSKCD150+48- subset dividing once every 145 days. [Method: BrdU DNA labeling for 10-13 days followed by a BrdU-free chase for up to 306 days]
Formal Description Interaction-ID: 17710	immunophenotype dormant-HSC (LRC-HSC, CD34-CD150+CD48-CD135-KSL) increases_activity of process quiescence in vivo

Comment	Around 70% of the HSC (CD34negLSKCD150+48-) population are in G0, and less than 2% are actively cycling, thus making them the most rare and by far the most quiescent LSK cell type. In contrast, 7-fold more of the CD34+LSK CD150+48- cells (MPP1) are actively cycling, and only 39% are in G0. As expected, MPPs expressing CD48 and CD135 are highly proliferative. [Method: in vitro: cell cycle analysis using Ki67-FITC and DAPI. in vivo: BrdU DNA labeling for 10-13 days followed by a BrdU-free chase for up to 306 days]
Formal Description Interaction-ID: 17719	immunophenotype HSC (CD34-CD135-CD150+CD48-KSL) decreases_activity of process cell cycle about 70% are in G0 phase in vivo and in vitro

Comment	Around 70% of the HSC (CD34negLSKCD150+48-) population are in G0 and less than 2% are actively cycling, thus making them the most rare and by far the most quiescent LSK cell type. In contrast, 7-fold more of the CD34+LSK CD150+48- cells (MPP1) are actively cycling, and only 39% are in G0. As expected, MPPs expressing CD48 and CD135 are highly proliferative. [Method: in vitro: cell cycle analysis using Ki67-FITC and DAPI. in vivo: BrdU DNA labeling for 10-13 days followed by a BrdU-free chase for up to 306 days]
Formal Description Interaction-ID: 17720	immunophenotype MPP (CD34+CD48-CD150+CD135-KSL) increases_activity of process cell cycle compared to the CD34- population; about 40% are in G0 phase in vivo and in vitro

Comment	Around 70% of the HSC (CD34negLSKCD150+48-) population are in G0 and less than 2% are actively cycling, thus making them the most rare and by far the most quiescent LSK cell type. In contrast, 7-fold more of the CD34+LSK CD150+48- cells (MPP1) are actively cycling, and only 39% are in G0. As expected, MPPs expressing CD48 and CD135 are highly proliferative. [Method: in vitro: cell cycle analysis using Ki67-FITC and DAPI. in vivo: BrdU DNA labeling for 10-13 days followed by a BrdU-free chase for up to 306 days]
Formal Description Interaction-ID: 17721	immunophenotype MPP (CD34+CD48+CD150-CD135+KSL) increases_activity of process cell cycle compared to the CD135- population; about 6% are in G0 phase in vivo and in vitro

Comment	By modeling BrdU decay in LRC-HSCs, over time we can reveal the presence of a dormant population that comprises about one-seventh of the CD34negLSKCD150+48- subset dividing once every 145 days. [Method: BrdU DNA labeling for 10-13 days followed by a BrdU-free chase for up to 306 days]
Formal Description Interaction-ID: 17722	immunophenotype dormant-HSC (LRC-HSC, CD34-CD150+CD48-CD135-KSL) decreases_activity of process cell cycle in vivo

Comment	Around 70% of the HSC (CD34negLSKCD150+48-) population are in G0 and less than 2% are actively cycling, thus making them the most rare and by far the most quiescent LSK cell type. In contrast, 7-fold more of the CD34+LSK CD150+48- cells (MPP1) are actively cycling, and only 39% are in G0. As expected, MPPs expressing CD48 and CD135 are highly proliferative. [Method: in vitro: cell cycle analysis using Ki67-FITC and DAPI.]
Formal Description Interaction-ID: 24260	immunophenotype MPP (CD34+CD48+CD150-CD135-KSL) decreases_activity of process quiescence compared to the CD135- population; about 9% are in G0 phase in vitro

Comment	Around 70% of the HSC (CD34negLSKCD150+48-) population are in G0 and less than 2% are actively cycling, thus making them the most rare and by far the most quiescent LSK cell type. In contrast, 7-fold more of the CD34+LSK CD150+48- cells (MPP1) are actively cycling, and only 39% are in G0. As expected, MPPs expressing CD48 and CD135 are highly proliferative. [Method: in vitro: cell cycle analysis using Ki67-FITC and DAPI.]
Formal Description Interaction-ID: 24261	immunophenotype MPP (CD34+CD48+CD150+CD135-KSL) decreases_activity of process quiescence compared to the CD135- population; about 18% are in G0 phase in vitro

Comment	HSC (CD34negLSKCD150+48-) is a highly quiescent HSC population. [Method: FACS]
Formal Description Interaction-ID: 24639	Immunophenotype HSC (CD34-CD135-CD150+CD48-KSL) increases_quantity of gene/protein Slamf1

Comment	HSC (CD34negLSKCD150+48-) is a highly quiescent HSC population. [Method: FACS]
Formal Description Interaction-ID: 24640	Immunophenotype HSC (CD34-CD135-CD150+CD48-KSL) decreases_quantity of gene/protein Cd34

Comment	HSC (CD34negLSKCD150+48-) is a highly quiescent HSC population. [Method: FACS]
Formal Description Interaction-ID: 24641	Immunophenotype HSC (CD34-CD135-CD150+CD48-KSL) decreases_quantity of gene/protein Cd48

Comment	MPP (CD34+CD48+CD150-CD135+KSL) is highly proliferative. [Method: FACS]
Formal Description Interaction-ID: 24642	Immunophenotype MPP (CD34+CD48+CD150-CD135+KSL) decreases_quantity of gene/protein Slamf1

Comment	MPP (CD34+CD48+CD150-CD135+KSL) is highly proliferative. [Method: FACS]
Formal Description Interaction-ID: 24643	Immunophenotype MPP (CD34+CD48+CD150-CD135+KSL) increases_quantity of gene/protein Cd34

Comment	MPP (CD34+CD48+CD150-CD135+KSL) is highly proliferative. [Method: FACS]
Formal Description Interaction-ID: 24644	Immunophenotype MPP (CD34+CD48+CD150-CD135+KSL) increases_quantity of gene/protein Cd48

Comment	MPP (CD34+CD48+CD150-CD135+KSL) is highly proliferative. [Method: FACS]
Formal Description Interaction-ID: 24645	Immunophenotype MPP (CD34+CD48+CD150-CD135+KSL) increases_quantity of gene/protein Flt3
Drugbank entries	Show/Hide entries for Flt3
Drugbank DB00398	Sorafenib antagonist FLT3
Drugbank DB01268	Sunitinib multitarget FLT3

Comment	HSC (CD34negLSKCD150+48-) is a highly quiescent HSC population. [Method: FACS]
Formal Description Interaction-ID: 24646	Immunophenotype HSC (CD34-CD135-CD150+CD48-KSL) decreases_quantity of gene/protein Flt3
Drugbank entries	Show/Hide entries for Flt3
Drugbank DB00398	Sorafenib antagonist FLT3
Drugbank DB01268	Sunitinib multitarget FLT3

Comment	MPPs can be purified by using the following surface markers: CD34+CD48-CD150+CD135-KSL. [Method: FACS.
Formal Description Interaction-ID: 24825	Immunophenotype MPP (CD34+CD48-CD150+CD135-KSL) increases_quantity of gene/protein Cd34

Comment	MPPs can be purified by using the following surface markers: CD34+CD48-CD150+CD135-KSL. [Method: FACS.
Formal Description Interaction-ID: 24826	Immunophenotype MPP (CD34+CD48-CD150+CD135-KSL) decreases_quantity of gene/protein Cd48

Comment	MPPs can be purified by using the following surface markers: CD34+CD48-CD150+CD135-KSL. [Method: FACS.
Formal Description Interaction-ID: 24827	Immunophenotype MPP (CD34+CD48-CD150+CD135-KSL) increases_quantity of gene/protein Slamf1

Comment	MPPs can be purified by using the following surface markers: CD34+CD48-CD150+CD135-KSL. [Method: FAC.
Formal Description Interaction-ID: 24828	Immunophenotype MPP (CD34+CD48-CD150+CD135-KSL) decreases_quantity of gene/protein Flt3
Drugbank entries	Show/Hide entries for Flt3
Drugbank DB00398	Sorafenib antagonist FLT3
Drugbank DB01268	Sunitinib multitarget FLT3

Comment	MPPs can be purified by using the following surface markers: CD34+CD48-CD150+CD135-KSL. [Method: FACS.
Formal Description Interaction-ID: 24829	Immunophenotype MPP (CD34+CD48-CD150+CD135-KSL) increases_quantity of gene/protein Kit
Drugbank entries	Show/Hide entries for Kit
Drugbank DB00398	Sorafenib antagonist KIT
Drugbank DB00619	Imatinib antagonist KIT
Drugbank DB01254	Dasatinib antagonist KIT
Drugbank DB01268	Sunitinib antagonist KIT
Drugbank DB01962	Phosphonotyrosine not specified KIT
Drugbank DB03431	Adenosine-5'-Diphosphate not specified KIT
Drugbank DB04868	Nilotinib antagonist KIT
Drugbank DB01962	Phosphonotyrosine not specified KIT
Drugbank DB03431	Adenosine-5'-Diphosphate not specified KIT
Drugbank DB04868	Nilotinib antagonist KIT

Comment	MPPs can be purified by using the following surface markers: CD34+CD48-CD150+CD135-KSL. [Method: FACS.
Formal Description Interaction-ID: 24831	Immunophenotype MPP (CD34+CD48-CD150+CD135-KSL) increases_quantity of gene/protein Ly6a

Comment	HSC (CD34negLSKCD150+48-) is a highly quiescent HSC population. [Method: FACS]
Formal Description Interaction-ID: 24832	Immunophenotype HSC (CD34-CD135-CD150+CD48-KSL) increases_quantity of gene/protein Kit
Drugbank entries	Show/Hide entries for Kit
Drugbank DB00398	Sorafenib antagonist KIT
Drugbank DB00619	Imatinib antagonist KIT
Drugbank DB01254	Dasatinib antagonist KIT
Drugbank DB01268	Sunitinib antagonist KIT
Drugbank DB01962	Phosphonotyrosine not specified KIT
Drugbank DB03431	Adenosine-5'-Diphosphate not specified KIT
Drugbank DB04868	Nilotinib antagonist KIT
Drugbank DB01962	Phosphonotyrosine not specified KIT
Drugbank DB03431	Adenosine-5'-Diphosphate not specified KIT
Drugbank DB04868	Nilotinib antagonist KIT

Comment	HSC (CD34negLSKCD150+48-) is a highly quiescent HSC population. [Method: FACS]
Formal Description Interaction-ID: 24833	Immunophenotype HSC (CD34-CD135-CD150+CD48-KSL) increases_quantity of gene/protein Ly6a

Comment	LRC-(BrdUcKit+) cells can be detected both near the endosteum and more centrally in the BM. [Method: detection of dormant HSCs by immunofluorescence staining for BrdU and cKit+ cells in bones of mice after 170 days chase]
Formal Description Interaction-ID: 35937	Immunophenotype dormant-HSC (LRC, Kit+) interacts (colocalizes) with tissue/cell line endosteum in vivo

Home
Contact

The Helmholtz Zentrum München Imprint and Privacy Policy apply.

© 2013 - Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH) Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany

Disclaimer: IBIS Databases and associated information are protected by copyright. This server and its associated data and services are for academic, non-commercial use only. The Helmholtz Zentrum München has no liability for the use of results, data or information which have been provided through this server. Neither the use for commercial purposes, nor the redistribution of IBIS database files to third parties nor the distribution of parts of files or derivative products to any third parties is permitted. Commercial users shall contact the Helmholtz Zentrum München for a separate users license.